Saturday 17 October 2026
Export ANTX’s income statement to Excel — free account
AN2 Therapeutics, Inc.
ANTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3% and free cash flow grew 7.91%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.
3.38
0.22
−6.11%
Follow ANTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (50.12%) | (44.56%) | (52.14%) | (45.91%) |
+8 more TTM periods Free account |
|
| (46.06%) | (40.93%) | (45.67%) | (41.21%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(48.75%) | (42.17%) | (68.68%) | (59.46%) | |
Free Cash Flow per Share |
(0.69) | (0.92) | (0.99) | (0.99) | |
Free Cash Flow |
(30.68) | (31.28) | (29.83) | (29.87) | |
| Other line items | |||||
Cash ROIC |
(19.88%) | (18.73%) | (26.86%) | (24.42%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.85 | 0.91 | 0.85 | 0.88 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.69) | (0.92) | (0.99) | (0.99) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates